Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer

Phase 2

Completed

Conditions: Recurrent Small Cell Lung Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Pegylated Irinotecan
Other: Pharmacological Study

First Posted Date: 2013-06-12

Last Posted Date: 2020-03-17

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 38

Registration Number: NCT01876446

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Rochester General Hospital, Rochester, New York, United States
🇺🇸
Linden Oaks Medical Campus, Rochester, New York, United States

Photodynamic Therapy During Surgery in Treating Patients With Non-small Cell Lung Cancer That Can Be Removed by Surgery

Phase 1

Completed

Conditions: Recurrent Non-Small Cell Lung Carcinoma
Stage IIIA Non-Small Cell Lung Cancer
Stage IIA Non-Small Cell Lung Carcinoma
Stage IIB Non-Small Cell Lung Carcinoma
Stage IIIB Non-Small Cell Lung Cancer

Interventions: Drug: Temoporfin
Procedure: Therapeutic Conventional Surgery
Drug: Photodynamic Therapy
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2013-05-15

Last Posted Date: 2022-07-22

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 8

Registration Number: NCT01854684

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery

Phase 1

Completed

Conditions: Advanced Adult Hepatocellular Carcinoma
Non-Resectable Hepatocellular Carcinoma

Interventions: Drug: Tivozanib (1.5mg)
Drug: Tivozanib (1mg)

First Posted Date: 2013-04-18

Last Posted Date: 2020-10-28

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 33

Registration Number: NCT01835223

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
Alkylating Agent-Related Acute Myeloid Leukemia
Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia
Refractory Anemia With Excess Blasts in Transformation

Interventions: Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Drug: Decitabine
Other: Laboratory Biomarker Analysis
Drug: Poly ICLC

First Posted Date: 2013-04-17

Last Posted Date: 2022-07-22

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 9

Registration Number: NCT01834248

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T

Not Applicable

Completed

Conditions: Recurrent Prostate Carcinoma
Stage IV Prostate Cancer
Metastatic Malignant Neoplasm in the Bone
Hormone-Resistant Prostate Cancer

Interventions: Other: Laboratory Biomarker Analysis
Radiation: Radiation Therapy

First Posted Date: 2013-04-16

Last Posted Date: 2021-08-05

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 15

Registration Number: NCT01833208

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Western New York Urology Associates LLC-Harlem, Cheektowaga, New York, United States

Interest in Smokeless Tobacco Product as a Substitution for Cigarettes in Current Smokers

Not Applicable

Terminated

Conditions: Tobacco Use Disorder

Interventions: Behavioral: smoking cessation intervention
Other: questionnaire administration
Other: quality-of-life assessment
Other: laboratory biomarker analysis
Other: ecigarettes

First Posted Date: 2013-02-27

Last Posted Date: 2022-09-13

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 72

Registration Number: NCT01800500

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer

Early Phase 1

Completed

Conditions: Stage IIIA Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer

Interventions: Combination Product: therapeutic lymphadenectomy (TEMLA) and Stereotactic Body radiation therapy (SBRT)
Other: quality-of-life assessment

First Posted Date: 2013-02-01

Last Posted Date: 2022-07-22

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 10

Registration Number: NCT01781741

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Varenicline or Nicotine Patch in Promoting Smoking Cessation Among Current Smokers

Not Applicable

Completed

Conditions: Tobacco Use Disorder

Interventions: Drug: nicotine patch
Drug: varenicline

First Posted Date: 2013-01-18

Last Posted Date: 2020-09-28

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 300

Registration Number: NCT01771627

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer

Not Applicable

Withdrawn

Conditions: Stage II Renal Cell Cancer
Stage III Renal Cell Cancer

Interventions: Drug: tivozanib
Procedure: therapeutic conventional surgery

First Posted Date: 2013-01-17

Last Posted Date: 2022-08-15

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT01769885

Breast and Cervical Cancer Educational Intervention for Latinas in Western New York

Not Applicable

Completed

Conditions: Breast Cancer
Cervical Cancer

Interventions: Other: educational intervention
Other: questionnaire administration

First Posted Date: 2013-01-04

Last Posted Date: 2022-10-05

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 959

Registration Number: NCT01760850

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy